ALEMBIC PHARMACEUTICALS

Indian pharma companies are increasingly focusing on innovative R&D, establishing dedicated research firms in Western countries. This strategy de-risks main businesses and attracts investment, with promising drug pipelines indicating future growth and global expansion in innovative drugs.

The premature ejaculation treatment market is projected to grow by USD 1.46 billion from 2024-2028, driven by high efficacy of off-label drugs and nanotechnology advancements. Key players include A. Menarini, Absorption Pharmaceuticals, Alembic Pharmaceuticals, and others. Challenges include side effects and pandemic-related access issues, with AI and telemedicine offering potential solutions.

Pharma firms invest in cosmo-dermatology due to rising demand for skincare, anti-ageing products, and aesthetic procedures, driven by pollution, higher incomes, and population growth. The derma market reached Rs 13,860 crore with an 8% CAGR, with cosmoderma contributing 32% of the segment. Cosmetic dermatology avoids price controls, offering a lucrative revenue stream.

Alembic Pharmaceuticals received FDA approval for Diltiazem Hydrochloride extended-release capsules, indicated for hypertension, chronic stable angina, and angina due to coronary artery spasm. The capsules are therapeutically equivalent to Bausch Health's Cardizem CD and have an estimated market size of $105.3 million by June 2024.

Alembic Pharmaceuticals received USFDA approval for Diltiazem Hydrochloride Extended-Release Capsules, managing hypertension and angina. Market size estimated at $105.3 million. Alembic now has 218 ANDA approvals.

Alembic Pharmaceuticals received FDA approval for Diltiazem Hydrochloride Extended-Release capsules, offering a generic alternative to Bausch Health’s Cardizem CD in the US market, valued at $105.3 million by June 2024. The approval adds to Alembic’s 218 ANDA approvals from the USFDA, reinforcing its position in the generics industry.

Alembic Pharmaceuticals receives US FDA approval for generic Diltiazem Capsules, therapeutically equivalent to Allergan's Dilacor XR Extended-Release Capsules, 120 mg, 180 mg, and 240 mg.

Alembic Pharmaceuticals received USFDA approval for Diltiazem Hydrochloride Extended-Release Capsules USP in 120 mg, 180 mg, and 240 mg formulations, therapeutically equivalent to Allergan's Dilacor XR, indicated for hypertension and chronic stable angina. The market size is estimated at $28.2 million by June 2024.

Alembic Pharmaceuticals receives FDA approval for Diltiazem Hydrochloride Extended-Release Capsules, dosages 120 mg, 180 mg, and 240 mg, indicated for hypertension treatment. The market size is projected at $28.2 million by June 2024, bringing Alembic's total ANDA approvals to 217.

Alembic Pharmaceuticals received USFDA final approval for Lamotrigine Extended-Release Tablets USP, 200 mg, 250 mg, and 300 mg, therapeutically equivalent to GSK's Lamictal XR. Indicated for seizures in patients aged 13+, with a $163 million market size.